カテゴリ： GlobalData, アメリカ, 企業調査

TG Therapeutics Inc (TGTX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：TG Therapeutics Inc (TGTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10034
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：64
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and autoimmune diseases. The company develops two therapies, namely, TG-1101 (ublituximab) and TGR-1202 for the treatment of hematological malignancies. TG-1101 glycoengineered monoclonal antibody that targets a unique epitope on the B-lymphocyte CD20 antigen and TG-1202 is an orally available PI3K delta inhibitor. Its other product candidates include inhibitors of IRAK4 and anti-PD-L1 and anti-GITR antibodies. The company also offers products and technologies for in-licensing, partnership, acquisition and/or investment. TG Therapeutics is headquartered in New York City, New York, the US.

TG Therapeutics Inc (TGTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TG Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
TG Therapeutics and Novimmune Enter into Agreement 12
TG Therapeutics Enters into Research Agreement with Fast Forward 13
TG Therapeutics Enters into Agreement with University of Nebraska Medical Center 14
TG Therapeutics Extends its Option Agreement with Checkpoint Therapeutics 15
TG Therapeutics Enters into Agreement with Checkpoint Therapeutics to Develop and Commercialize Immuno-Oncology Targeted Antibodies 16
TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 17
Licensing Agreements 19
TG Therapeutics Enters into Licensing Agreement with Jiangsu Hengrui 19
TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20
TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 21
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 23
TG Therapeutics Enters Into Licensing Agreement With Ildong Pharma For Ublituximab 24
TG Therapeutics Enters Into Licensing Agreement With LFB Biotechnologies And GTC Biotherapeutics For Ublituximab 25
Equity Offering 26
TG Therapeutics Raises USD57.5 Million in Underwritten Public Offering of Shares 26
TG Therapeutics Raises USD50 Million in Public Offering Of Common Stock 28
TG Therapeutics Completes Private Placement Of Shares For US$18 Million 29
TG Therapeutics Completes Underwriters’ Exercise Of Over-Allotment Option For Public Offering Of Shares For US$5.3 Million 30
Manhattan Pharma Completes Private Placement Of Shares For US$25 Million 32
TG Therapeutics Inc – Key Competitors 33
TG Therapeutics Inc – Key Employees 34
TG Therapeutics Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Aug 07, 2018: TG Therapeutics provides business update and reports second quarter 2018 financial results 36
Nov 08, 2017: TG Therapeutics Provides Business Update and Reports Third Quarter 2017 Financial Results 37
Aug 09, 2017: TG Therapeutics Provides Business Update and Reports Second Quarter 2017 Financial Results 38
May 05, 2017: TG Therapeutics Provides Business Update and Reports First Quarter 2017 Financial Results 40
Mar 10, 2017: TG Therapeutics Announces Fourth Quarter and Year-End 2016 Financial Results and Business Update 42
Corporate Communications 43
Jun 04, 2018: TG Therapeutics Names Adam Waldman As Chief Commercial Officer 43
Product News 44
06/26/2017: TG Therapeutics Recaps Data from Triple Combination Therapy Trials at the 22nd European Hematology Association Annual Congress 44
05/18/2017: TG Therapeutics Announces Clinical Data Presentations at the Upcoming 22nd European Hematology Association Annual Congress 46
Product Approvals 47
Jan 24, 2017: TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for the Treatment of Diffuse Large B-cell Lymphoma 47
Jan 09, 2017: TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for Treatment of Chronic Lymphocytic Leukemia 48
Clinical Trials 49
Jan 24, 2018: TG Therapeutics Announces Data Presentation at the Upcoming Third Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018 49
Dec 11, 2017: TG Therapeutics Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting 50
Dec 08, 2017: TG Therapeutics Recaps Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting 53
Nov 01, 2017: TG Therapeutics Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting 55
Oct 26, 2017: TG Therapeutics Announces Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS – ACTRIMS Meeting 57
Oct 16, 2017: TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial 58
Sep 05, 2017: TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial 59
Aug 10, 2017: TG Therapeutics Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial 60
Jun 15, 2017: TG Therapeutics Announces Follow-Up Data from the Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma 61
May 23, 2017: TG Therapeutics Announces Successful Outcome from Pre-Planned Interim Analysis by Independent DSMB in the UNITY-CLL Phase 3 Trial 62
Other Significant Developments 63
May 08, 2018: TG Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TG Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TG Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
TG Therapeutics and Novimmune Enter into Agreement 12
TG Therapeutics Enters into Research Agreement with Fast Forward 13
TG Therapeutics Enters into Agreement with University of Nebraska Medical Center 14
TG Therapeutics Extends its Option Agreement with Checkpoint Therapeutics 15
TG Therapeutics Enters into Agreement with Checkpoint Therapeutics to Develop and Commercialize Immuno-Oncology Targeted Antibodies 16
TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 17
TG Therapeutics Enters into Licensing Agreement with Jiangsu Hengrui 19
TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20
TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 21
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 23
TG Therapeutics Enters Into Licensing Agreement With Ildong Pharma For Ublituximab 24
TG Therapeutics Enters Into Licensing Agreement With LFB Biotechnologies And GTC Biotherapeutics For Ublituximab 25
TG Therapeutics Raises USD57.5 Million in Underwritten Public Offering of Shares 26
TG Therapeutics Raises USD50 Million in Public Offering Of Common Stock 28
TG Therapeutics Completes Private Placement Of Shares For US$18 Million 29
TG Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For US$5.3 Million 30
Manhattan Pharma Completes Private Placement Of Shares For US$25 Million 32
TG Therapeutics Inc, Key Competitors 33
TG Therapeutics Inc, Key Employees 34
TG Therapeutics Inc, Subsidiaries 35

List of Figures
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[TG Therapeutics Inc (TGTX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Jardine Lloyd Thompson Group plc：企業の戦略・SWOT・財務分析
    Jardine Lloyd Thompson Group plc - Strategy, SWOT and Corporate Finance Report Summary Jardine Lloyd Thompson Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Bone Biologics Corp (BBLG)：企業の財務・戦略的SWOT分析
    Summary Bone Biologics Corp (Bone Biologics) is a biotechnology company that develops orthobiologic products. It develops NELL-1, a recombinant human protein growth factor, which is essential for normal bone development. It offers bone graft substitutes for spine fusion. Bone Biologics also offers N …
  • Daiwa Can Co., Ltd.：企業の戦略・SWOT・財務情報
    Daiwa Can Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daiwa Can Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Syneron Medical Ltd：企業の戦略的SWOT分析
    Syneron Medical Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Pharmaxis Ltd (PXS)-製薬・医療分野：企業M&A・提携分析
    Summary Pharmaxis Ltd (Pharmaxis) is a pharmaceutical research company that develops and commercialize healthcare products. The company offers products such as aridol which identify twitchy and assist in diagnosing and managing asthma, and bronchitol which restores normal lung hydration, improves lu …
  • Tsurumi Manufacturing Co Ltd (6351)：企業の財務・戦略的SWOT分析
    Tsurumi Manufacturing Co Ltd (6351) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Centene Corp (CNC)-製薬・医療分野：企業M&A・提携分析
    Summary Centene Corp (Centene) is a healthcare service provider that offers services to government sponsored healthcare programs with focus on under-insured and uninsured individuals. It provides health plans through Medicaid, Medicare and Health Insurance Marketplace contracts; and other health sol …
  • Religare Enterprises Limited：企業のM&A・事業提携・投資動向
    Religare Enterprises Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Religare Enterprises Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Telstra Corporation Limited：企業の戦略・SWOT・財務情報
    Telstra Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Telstra Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • BioScrip Inc (BIOS)：医療機器：M&Aディール及び事業提携情報
    Summary BioScrip Inc (BioScrip), formerly MIM Corp is a healthcare service provider that provides infusion care services. The hospital offers a range of infusion services, PBM services and respiratory services. It provides infusion therapy services such as antimicrobial drugs, factor replacement the …
  • Sermonix Pharmaceuticals LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary Sermonix Pharmaceuticals LLC (Sermonix) is a biotechnology company develops female-specific oncology products. The company provides lead product such as lasofoxifene, which is a selective estrogen receptor modulator. Its lasofoxifene is used in the treatment of common disorders affecting wom …
  • EPAM Systems Inc (EPAM)：企業の財務・戦略的SWOT分析
    EPAM Systems Inc (EPAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • ZoomMed Inc (ZMD)：医療機器：M&Aディール及び事業提携情報
    Summary ZoomMed Inc (ZoomMed) is a technical service provider that offers web solutions for medical sectors. The company’s product includes ZoomMed Network, ZRx Prescriber, PraxisLab, and EvPsych. It builds and operates a clinical information exchange platform between physicians and specialists, pat …
  • A. K. Capital Services Ltd (530499)：企業の財務・戦略的SWOT分析
    A. K. Capital Services Ltd (530499) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Aushon BioSystems Inc-医療機器分野：企業M&A・提携分析
    Summary Aushon BioSystems Inc (Aushon) is a medical device provider that offers biomarker measurement and analysis products. The company provides biomarker therapeutic areas in microarray printing technology. Its products include ciraplex assay, cirascan imaging and cirasoft analysis and cira servic …
  • XsunX Inc (XSNX)：企業の財務・戦略的SWOT分析
    XsunX Inc (XSNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Clovis Oncology Inc (CLVS)-医療機器分野：企業M&A・提携分析
    Summary Clovis Oncology Inc (Clovis) is a biopharmaceutical company that acquires, develops and commercializes new anti-cancer agents. The company's development programs are targeted at specific cancer indications, combining personalized medicine with companion diagnostics. It develops and commercia …
  • Amryt Pharma Plc (AMYT)：企業の財務・戦略的SWOT分析
    Amryt Pharma Plc (AMYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • TechnologyOne Limited (TNE)：企業の財務・戦略的SWOT分析
    TechnologyOne Limited (TNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • iNova Pharmaceuticals (Australia) Pty Ltd：企業の戦略的SWOT分析
    iNova Pharmaceuticals (Australia) Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆